Company intelligence / Profile preview

Xycorp

Malvern, Pennsylvania, United States

Ownership: Private
Employees: ~16
Development stage: Other

Overview

Lead candidate XC001 (encoberminogene rezmadenovec) in Phase 2b EXACT-2 trial for refractory angina in coronary artery disease; first patient dosed July 2025. Secondary candidate XC002 in discovery for cardiac tissue damage post-heart attack.

Therapeutic areas: Cardiovascular
Modalities: Gene therapyAAV based gene therapy
Industry: Biotech

Beyond the preview

Go deeper on Xycorp.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xycorp.

Explore the full profile